AUTHORS
Zdenek Krejcik, PhD, MSc, Marek Jedlicka2, David Kundrat3, Monika Kaisrlikova, MSc4, Zuzana Pinc5, Cyril Salek, CS6, Marketa Stastna Markova7, Monika Belickova8
AFFILIATIONS
1 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
3 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
4 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
5 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
6 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
7 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
8 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
ABSTRACT
Introduction: VEXAS syndrome is a rare autoinflammatory disorder caused by somatic mutations in the X-linked UBA1 gene and is frequently associated with cytopenias, clonal hematopoiesis, and myelodysplastic neoplasms (MDS). Additional somatic mutations and genetically distinct clones may contribute to disease heterogeneity, but their biological significance and the relationship between VEXAS and MDS remain incompletely understood. We characterized clonal architecture and lineage distribution in patients with VEXAS and compared CD34+ transcriptional profiles among healthy controls, VEXAS and MDS patients.
Methods: Targeted single-cell DNA sequencing (scDNA-seq) was performed on peripheral blood leukocytes collected at diagnosis from five patients with VEXAS carrying additional somatic mutations using a microfluidic targeted single-cell DNA sequencing platform (Tapestri; Mission Bio) and a custom DNA panel. DNA genotypes were integrated with immunophenotyping using a 42-antigen oligonucleotide-conjugated antibody panel (TotalSeq-D Human Heme Oncology Cocktail; BioLegend). Bulk RNA sequencing (RNA-seq) was performed on magnetically enriched bone marrow CD34+ cells collected at diagnosis from eight different patients with VEXAS, five healthy male controls, and ten age-comparable male patients with MDS without VEXAS. Differentially expressed genes were identified at a false discovery rate (FDR) < 0.05. Genes consistently altered in VEXAS relative to both control and MDS groups were assessed by over-representation analysis (ORA) using Molecular Signatures Database (MSigDB) C5 Gene Ontology Biological Process and C2 Reactome sets. A composite early lymphoid score and a separate granulocytic progenitor score were calculated from published adult bone marrow CD34+ signatures derived from an independent single-cell atlas in MSigDB C8. Age-adjusted and leave-one-out analyses assessed robustness.
Results: In addition to UBA1 mutations, scDNA-seq identified variants in DNMT3A, TET2, U2AF1, ETV6, SETBP1, and ASXL1. Clonal architecture included UBA1-only clones, clones carrying UBA1 together with an additional variant, and parallel clones harboring other mutations. Genotype-immunophenotype integration showed a predominantly myeloid distribution of UBA1-mutant clones, with generally low but patient-variable representation in lymphoid populations.
RNA-seq identified 332 differentially expressed genes between VEXAS and healthy controls, including 134 upregulated and 198 downregulated genes. Sixty genes were consistently upregulated and 66 downregulated in VEXAS relative to both healthy controls and MDS. Downregulated genes included DNTT, RAG1, RAG2, EBF1, PAX5, VPREB1, IGLL1, BLNK, and CD79B and were enriched for B-cell activation, B-cell differentiation, and lymphocyte differentiation. Upregulated genes included IL1R1, IL1RAP, HCK, ALOX5, C3AR1, CLEC5A, NCF2, and CASP1 and were enriched for neutrophil degranulation, interleukin signaling, and IL-1 family signaling (all FDR < 0.05).
The composite early lymphoid score based on external signatures was lower in VEXAS than in healthy controls and MDS after age adjustment (both FDR < 0.05). This finding remained significant when VEXAS was compared with the MDS subgroup without detected mutations (nominal p < 0.05) and was stable in leave-one-out analyses. The granulocytic progenitor score was not significantly increased in VEXAS.
Conclusions: Independent single-cell and transcriptomic cohorts provide complementary evidence of lineage-imbalanced hematopoiesis in VEXAS. The predominantly myeloid distribution of UBA1-mutant clones in peripheral blood was paralleled in an independent cohort by depletion of an early lymphoid transcriptional program in bone marrow CD34+ cells and enrichment of innate immune, neutrophil-associated, and IL-1-associated genes. These findings are consistent with reduced early lymphoid commitment or altered progenitor composition and a predominantly myeloid representation of UBA1-mutant clones.
This work was supported by the Ministry of Health of the Czech Republic (NU23-10-00160), MH CZ-DRO (UHKT, 00023736), and BBMRInv (P JAC; reg. no. CZ.02.01.01/00/23_015/0008196), co-funded by the EU.
DISCLOSURES
Zdenek Krejcik, PhD, MSc: No relevant conflicts of interest to declare.